| __timestamp | Intra-Cellular Therapies, Inc. | Novo Nordisk A/S |
|---|---|---|
| Wednesday, January 1, 2014 | 10337679 | 26760000000 |
| Thursday, January 1, 2015 | 18187286 | 32169000000 |
| Friday, January 1, 2016 | 24758063 | 32339000000 |
| Sunday, January 1, 2017 | 23666957 | 32124000000 |
| Monday, January 1, 2018 | 30099855 | 33313000000 |
| Tuesday, January 1, 2019 | 64947625 | 35830000000 |
| Wednesday, January 1, 2020 | 186363444 | 36886000000 |
| Friday, January 1, 2021 | 272611040 | 41058000000 |
| Saturday, January 1, 2022 | 358782000 | 50684000000 |
| Sunday, January 1, 2023 | 409864000 | 61598000000 |
| Monday, January 1, 2024 | 67377000000 |
Unleashing the power of data
In the ever-evolving pharmaceutical landscape, cost management is pivotal. Novo Nordisk A/S and Intra-Cellular Therapies, Inc. offer a fascinating study in contrasts. Over the past decade, Novo Nordisk's Selling, General, and Administrative (SG&A) expenses have surged by approximately 130%, reaching a staggering $61.6 billion in 2023. This reflects their expansive global operations and robust market presence. Meanwhile, Intra-Cellular Therapies, Inc., a burgeoning player, has seen its SG&A expenses skyrocket by nearly 3,900%, from $10.3 million in 2014 to $409 million in 2023. This dramatic increase underscores their aggressive growth strategy and investment in market penetration. As these companies navigate the complexities of the pharmaceutical industry, their SG&A trends offer valuable insights into their strategic priorities and operational efficiencies.
Eli Lilly and Company and Novo Nordisk A/S: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Novo Nordisk A/S or Pharming Group N.V.
Novo Nordisk A/S or Lantheus Holdings, Inc.: Who Manages SG&A Costs Better?
Breaking Down SG&A Expenses: Novo Nordisk A/S vs ACADIA Pharmaceuticals Inc.
Cost Management Insights: SG&A Expenses for Novo Nordisk A/S and Galapagos NV
Operational Costs Compared: SG&A Analysis of Novo Nordisk A/S and Novavax, Inc.
Selling, General, and Administrative Costs: Novo Nordisk A/S vs MiMedx Group, Inc.
Breaking Down SG&A Expenses: argenx SE vs Intra-Cellular Therapies, Inc.
Comparing SG&A Expenses: Intra-Cellular Therapies, Inc. vs Merus N.V. Trends and Insights
Who Optimizes SG&A Costs Better? Intra-Cellular Therapies, Inc. or Soleno Therapeutics, Inc.
Intra-Cellular Therapies, Inc. or Evotec SE: Who Manages SG&A Costs Better?
Intra-Cellular Therapies, Inc. vs Xencor, Inc.: SG&A Expense Trends